Last updated: 2026-09-16 11:45:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Dermata Therapeutics, Inc. (DRMA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.15, with a market capitalisation of $5.70M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.95 to $6.22. This page covers its latest market performance, valuation, price trends and company information.
$5.70M | |
$1.15 | |
$16,680.00 | |
$0.95 | |
$1.13 | |
68.00 | |
740.12K | |
-- | |
$6.22 | |
$0.95 | |
-- | |
-- |
Dermata Therapeutics, Inc. (DRMA) is trading at $1.15 in pre-market trading as of 2026-09-16 10:30:00, up 1.77% ($0.02) from the previous close of $1.13
Pre-market trading shows how investors are pricing DRMA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Dermata Therapeutics, Inc. (DRMA) moved from $1.21 to $1.15, representing a decline of 4.96% ($0.06).
The stock traded between $1.06 and $1.31 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 29.76 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.8%
DRMA is currently trading at $1.15, placing it 3.8% of the way from its 52-week low of $0.95 to its 52-week high of $6.22. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 9 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Dermata Therapeutics, Inc. (DRMA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.